Wuhan Hvsen Biotechnology Co.,Ltd. (SHE:300871)
China · Delayed Price · Currency is CNY 27.18
+0.27 (1.00%)
Jan 23, 2026, 3:04 PM CST
Wuhan Hvsen Biotechnology Revenue
Wuhan Hvsen Biotechnology had revenue of 437.33M CNY in the quarter ending September 30, 2025, with 22.76% growth. This brings the company's revenue in the last twelve months to 1.67B, up 48.74% year-over-year. In the year 2024, Wuhan Hvsen Biotechnology had annual revenue of 1.20B with 17.71% growth.
Revenue (ttm)
1.67B
Revenue Growth
+48.74%
P/S Ratio
3.57
Revenue / Employee
1.62M
Employees
1,028
Market Cap
5.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.20B | 180.57M | 17.71% |
| Dec 31, 2023 | 1.02B | -3.14M | -0.31% |
| Jan 1, 2023 | 1.02B | 26.68M | 2.68% |
| Jan 1, 2022 | 996.22M | 218.76M | 28.14% |
| Dec 31, 2020 | 777.46M | 350.24M | 81.98% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novogene | 2.17B |
| Kexing Biopharm | 1.52B |
| Xiangxue Pharmaceutical | 1.47B |
| Shenzhen Weiguang Biological Products | 1.14B |
| Beijing Konruns Pharmaceutical | 871.31M |
| R&G PharmaStudies | 789.45M |
| PharmaResources (Shanghai) | 667.47M |
| Hangzhou Biotest Biotech | 478.69M |